Background: Patients suffering from vascular disease present unique challenges to any clinician seeking to facilitate wound healing in this cohort. Traditional methods of assisted wound closure such as skin grafting or autologous flaps, require an operating theatre and often necessitate general anaesthesia; they are often avoided in this cohort due to high risk of systemic complications and failure. Biodegradeable temporising matrix (BTM) has shown promise in overcoming many of the barriers associated with wound healing in the vascular surgical cohort, however, its applicability is limited to wounds that are more superficial in nature. Novosorb MTX provides the same polyurethane matrix as BTM but without the sealing membrane. It can therefore be utilised more broadly in vascular surgery to include deeper, complex wounds where contraction is acceptable. Methods: Prospective data collection was undertaken for all patients who have been treated with Novosorb MTX since October 2023. Patient demographics and outcome data including wound aetiology, location of Novosorb MTX application, presence of wound closure and time to wound closure were recorded. Results: Novosorb MTX has been applied to 10 wounds in 10 patients. All were performed in a ward environment without the need for anaesthesia. The majority (9/10) were for the treatment of diabetic foot wounds. To date, wound closure has been recorded in 5/10 wounds with the time to closure ranging from 15-21 weeks. Of the remaining 5 wounds, 3 are on a healing trajectory, 1 patient died prior to wound closure and 1 patient required surgical debridement of the wound due to inadequate treatment of the index infection. Conclusion: Novosorb MTX is a safe and effective treatment to facilitate wound closure in vascular surgical patients. Its ability to be used in deep wounds outside of the operating theatre environment provides an advantage over other methods of assisted wound closure in this high-risk patient cohort.